Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA ...

SHANGHAI, May 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the supplemental application ...

THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Xgeva (denosumab) is a prescription drug used to treat certain bone conditions and prevent bone complications in people with cancer. Xgeva’s cost may depend on factors such as your dosage and whether ...

Please provide your email address to receive an email when new articles are posted on . Lyu and colleagues analyzed electronic medical records data from 151 adults aged at least 45 years identified as ...

Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos (denosumab-nxxp) injection 60 mg/ml and Bilprevda (denosumab-nxxp) injection 120 mg/1.7 ...

Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the ...

FDA Approves Amgen's XGEVA (TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors --First Bone Targeted Therapy for Cancer Patients to Be ...

August 11, 2009 — Denosumab injections are associated with lower fracture rate in postmenopausal women with osteoporosis, according to the results of an international, randomized, double-blind, ...

"Today's approval of XGEVA illustrates what is possible when scientific innovation, commitment and investment come together to advance medicine," said Kevin Sharer, chairman and chief executive ...